<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146119</url>
  </required_header>
  <id_info>
    <org_study_id>BVX-004</org_study_id>
    <nct_id>NCT01146119</nct_id>
  </id_info>
  <brief_title>Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)</brief_title>
  <official_title>A Phase II, Randomized, Two Stage, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of an Intramuscular Influenza Vaccine (Multimeric-001) Injected to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BiondVax Pharmaceuticals ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BiondVax Pharmaceuticals ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, two stage, double-blind, placebo-controlled&#xD;
      administration study comprising 200 healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II multi-center, randomized, two stage, double-blind, placebo-controlled&#xD;
      study comprising 200 participants. Eligible subjects will be randomized to receive one of the&#xD;
      following administrations (as two single IM injections with an interval of 21 days between&#xD;
      each injection Administration A: Prime twice with Adjuvanted Multimeric-001 500 mcg - 64&#xD;
      subjects.&#xD;
&#xD;
      Administration B: PBS (Placebo) twice - 32 subjects. Administration C: Adjuvanted PBS&#xD;
      (Placebo)twice - 32 subjects. Participants from administrations A and B will be further&#xD;
      immunized with a 15% dose of commercial seasonal trivalent vaccine for 2011 on day 81.&#xD;
&#xD;
      Administration D: Adjuvanted Multimeric-001 500 mcg coadministered once with 15% of TIV dose&#xD;
      - 24 subjects. Administration E: Adjuvanted Multimeric-001 500 mcg coadministered once with&#xD;
      50% of TIV dose - 24 subjects Administration group F: PBS (Placebo) co-administered once with&#xD;
      50% of TIV dose - 24 subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>From day 0 until day 221</time_frame>
    <description>Number of Participants with Adverse Events possible/probably related to the study drug in each group were similar in the experimental and control groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti Multimeric-001 antibodies</measure>
    <time_frame>21 days after second immunization with M-001</time_frame>
    <description>Direct Elisa assay to test the titer of human antibodies that recognize the Multimeric-001 protein. Humoral immunity was manifested 21 and 60 days post immunization by significantly elevated anti-M-001 IgG levels among subjects administered twice with adjuvanted M-001</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemagglutination Inhibition (HAI) test for anti influenza antibodies</measure>
    <time_frame>21 days post co administration of M-001 and TIV 50%</time_frame>
    <description>The serum is tested for its ability to adhere to influenza virus and thus inhibit the Hemagglutination reaction. Adjuvanted M-001 co-administered with partial dose of TIV (Vaxigrip, 50%) was effective in enhancing immunity to influenza-related antigens, as manifested by increased HAI antibody responses toward viruses contained in the TIV as well as toward non-TIV virus strains.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cellular Immunogenicity</measure>
    <time_frame>21 days after co administration of M-001 and TIV 50%</time_frame>
    <description>Elevated proliferation of lymphocytes following in vitro incubation with M-001. The proliferation was associated with IFN gamma secretion</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Multimeric-001, Adjuvanted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>64 subjects received 2 injections of Adjuvanted Multimeric-001, 500 mcg with an interval of 21 days and then 60 days later were further immunized with a 15% dose of commercial seasonal trivalent vaccine (season 2011).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBS and TIV 15%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>32 subjects received 2 injections of PBS (Phosphate Buffered Saline) with an interval of 21 days and then were further immunized 60 days later with a 15% dose of commercial seasonal trivalent vaccine (season 2011).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Adjuvanted</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>32 subjects received Adjuvanted PBS (Placebo) with an interval of 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Co-administration M-001 and TIV 15%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects received 2 injections on the same day, one injection containing Adjuvanted Multimeric-001 500 mcg and the other containing TIV 15%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Co administration of M-001 and TIV 50%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects received 2 injections on the same day, one injection containing Adjuvanted Multimeric-001 500 mcg and the other containing TIV 50%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Co administration of PBS and TIV 50%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 subjects received 2 injections on the same day, one injection containing PBS and the other containing TIV 50%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multimeric-001, 500 mcg</intervention_name>
    <description>Adjuvanted Multimeric-001 was administered twice with an interval of 19-23 days.</description>
    <arm_group_label>Co administration of M-001 and TIV 50%</arm_group_label>
    <arm_group_label>Co-administration M-001 and TIV 15%</arm_group_label>
    <arm_group_label>Multimeric-001, Adjuvanted</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted PBS</intervention_name>
    <description>Adjuvanted PBS was administered twice with an interval of 19-23 days.</description>
    <arm_group_label>Placebo, Adjuvanted</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PBS and TIV 15%</intervention_name>
    <description>PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 15% dose of commercial seasonal trivalent vaccine (season 2011) was administered.</description>
    <arm_group_label>PBS and TIV 15%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PBS and TIV 50%</intervention_name>
    <description>PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 50% dose of commercial seasonal trivalent vaccine (season 2011) was administered.</description>
    <arm_group_label>Co administration of PBS and TIV 50%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males and females between the age of 18 and 49 years (inclusive).&#xD;
&#xD;
          -  Subjects who provide written informed consent to participate in the study.&#xD;
&#xD;
          -  Subjects able to adhere to the visit schedule and protocol requirements and be&#xD;
             available to complete the study.&#xD;
&#xD;
          -  Haematology, chemistry and urinalysis values with no clinical significance or do not&#xD;
             reflect a medical condition which, according to the physician's judgment, might&#xD;
             confound the results of the study or pose additional risk to the subject by&#xD;
             participation in the study.&#xD;
&#xD;
          -  Female of childbearing age must agree to use an acceptable method of contraception and&#xD;
             male subjects should use a condom throughout the study period (until termination&#xD;
             visit) if female partner is not using an effective contraceptive method.&#xD;
&#xD;
          -  Subjects who are seronegative to at least one of the strains included in the seasonal&#xD;
             vaccine against influenza for 2011.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of significant medical disorder, which in the investigator's judgment,&#xD;
             might confound the results of the study or pose additional risk to the subject by&#xD;
             participation in the study.&#xD;
&#xD;
          -  Subjects with known Guillain Barr√© Syndrome in the past.&#xD;
&#xD;
          -  Two or more hospitalizations within the last year prior to screening visit.&#xD;
&#xD;
          -  Known bleeding disorders including hemophilia or thrombocytopenia, or treatment with&#xD;
             anticoagulant therapy (risk of bleeding with intramuscular injection).&#xD;
&#xD;
          -  Immunocompromised patients and those receiving concomitant immunosuppressive therapy;&#xD;
             or other immune modulating drugs including chronic steroid treatment.&#xD;
&#xD;
          -  Subjects who have been immunized with anti-influenza vaccine or infected by influenza&#xD;
             virus within eight months prior to the screening visit.&#xD;
&#xD;
          -  Administration of any vaccine 30 days before the screening visit.&#xD;
&#xD;
          -  Known hypersensitivity to previous influenza vaccination.&#xD;
&#xD;
          -  Use of an influenza antiviral medication within 4 weeks of vaccination.&#xD;
&#xD;
          -  Known hypersensitivity and/or allergy to any drug or vaccine.&#xD;
&#xD;
          -  Known hypersensitivity to egg proteins (eggs or egg products), chicken proteins, or&#xD;
             any of the vaccine components.&#xD;
&#xD;
          -  Known history of drug or alcohol abuse.&#xD;
&#xD;
          -  Any clinically significant abnormality upon physical examination or in the clinical&#xD;
             laboratory tests at screening visit which, according to the physician's judgment,&#xD;
             might confound the results of the study or pose additional risk to the subject by&#xD;
             participation in the study.&#xD;
&#xD;
          -  Increased liver enzymes more than 2.5 times above the upper reference level.&#xD;
&#xD;
          -  Positive serology for HIV, HCV antibody or HBsAg.&#xD;
&#xD;
          -  Any acute medical situation (e.g. acute infection, ongoing flu symptoms) with or&#xD;
             without fever within 48 hours of vaccination, which is considered of significance by&#xD;
             the Principal Investigator.&#xD;
&#xD;
          -  Pregnant or lactating women at entry to study and those who are unwilling to agree to&#xD;
             continue to use acceptable methods of contraception for two months after completion of&#xD;
             the study (if applicable).&#xD;
&#xD;
          -  Positive blood pregnancy test on screening.&#xD;
&#xD;
          -  Subjects who participated in any clinical study within 30 days prior to study entry&#xD;
&#xD;
          -  Subjects who are non-cooperative or unwilling to sign consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Atsmon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Center, Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yosef Caraco, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Center, Hadassah Medical Center, Jerusalem</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Center, Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center, Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>June 13, 2010</study_first_submitted>
  <study_first_submitted_qc>June 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2010</study_first_posted>
  <last_update_submitted>July 30, 2012</last_update_submitted>
  <last_update_submitted_qc>July 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HAI</keyword>
  <keyword>Influenza</keyword>
  <keyword>prime</keyword>
  <keyword>boost</keyword>
  <keyword>immune response</keyword>
  <keyword>seroconversion</keyword>
  <keyword>universal</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

